The αvβ3 integrin as a tumor homing ligand for lymphocytes

European Journal of Immunology

Volumn 34, Issue 6, 2004, Pages 1608-1616

  Legler, Daniel F ^a,c   Johnson Léger, Caroline ^b   Wiedle, Guido ^b   Bron, Claude ^a   Imhof, Beat A ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

v 3 integrin; Glycosylphosphatidylinostol anchored proteins; Lymphocytes; Painting; Tumor homing

Indexed keywords

ALPHA INTEGRIN; ANTINEOPLASTIC AGENT; CD51 ANTIGEN; GLYCOSYLPHOSPHATIDYLINOSITOL; RECOMBINANT PROTEIN; HOMING RECEPTOR; VITRONECTIN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL ADHESION; CELL SPECIFICITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENDOTHELIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; LEWIS CARCINOMA; LIGAND BINDING; LYMPHOCYTE HOMING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR IMMUNITY; TUMOR VASCULARIZATION; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; FLOW CYTOMETRY; IMMUNOLOGY; LEUKEMIA CELL LINE; METHODOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CARCINOMA, LEWIS LUNG; CELL ADHESION; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTEGRIN ALPHAVBETA3; JURKAT CELLS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; RECEPTORS, LYMPHOCYTE HOMING; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 4544352471     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200424938     Document Type: Article

References (47)

1. Piali, L., Fichtel, A., Terpe, H. J., Imhof, B. A. and Gisler, R. H., Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med. 1995. 181: 811-816.
2. Griffioen, A. W., Damen, C. A., Martinotti, S., Blijham, G. H. and Groenewegen, G., Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res. 1996, 56: 1111-1117.
3. Wu, N. Z., Klitzman, B., Dodge, R. and Dewhirst, M. W., Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res. 1992. 52: 4265-4268.
4. Carlos, T. M., Leukocyte recruitment at sites of tumor: dissonant orchestration. J. Leukoc. Biol. 2001. 70: 171-184.
5. Griffioen, A. W., Damen, C. A., Blijham, G. H. and Groenewegen, G., Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 1996. 88: 667-673.
6. Dvorak, H. F., Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986. 315: 1650-1659.
7. Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., Roederer, M. and Davis, M. M., Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 1999. 5: 677-685.
8. Hanahan, D. and Folkman, J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996. 86: 353-364.
9. Risau, W., Mechanisms of angiogenesis. Nature 1997. 386: 671-674.
10. Carmeliet, P., Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000. 6: 389-395.
11. Brooks, P. C., Clark, R. A. and Cheresh, D. A., Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994. 264: 569-571.
12. Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G. and Cheresh, D. A., Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994. 79: 1157-1164.
13. Brooks, P. C., Stromblad, S., Klemke, R., Visscher, D., Sarkar, F. H. and Cheresh, D. A., Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 1995. 96: 1815-1822.
14. Eliceiri, B. P., Klemke, R., Stromblad, S. and Cheresh, D. A., Integrin alpha(v)beta(3) requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J. Cell Biol. 1998. 140: 1255-1263.
15. Hammes, H. P., Brownlee, M., Jonczyk, A., Suffer, A. and Preissner, K. T., Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med. 1996. 2: 529-533.
16. Reynolds, L. E., Wyder, L., Lively, J. C., Taverna, D., Robinson, S. D., Huang, X., Sheppard, D., Hynes, R. O. and Hodivala-Dilke, K. M., Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat. Med. 2002. 8: 27-34.
17. Gasparini, G., Brooks, P. C., Biganzoli, E., Vermeulen, P. B., Bonoldi, E., Dirix, L. Y., Ranieri, G., Miceli, R. and Cheresh, D. A., Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin. Cancer Res. 1998. 4: 2625-2634.
18. Vonlaufen, A., Wiedle, G., Borisch, B., Birrer, S., Luder, P. and Imhof, B. A., Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod. Pathol. 2001. 14: 1126-1132.
19. Kageshita, T., Hamby, C. V., Hirai, S., Kimura, T., Ono, T. and Ferrone, S., Differential clinical significance of alpha(v)beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. Int. J. Cancer 2000. 89: 153-159.
20. Max, R., Gerritsen, R. R., Nooijen, P. T., Goodman, S. L., Sutter, A., Keilholz, U., Ruiter, D. J. and De Waal, R. M., Immunohistochemical analysis of integrin alpha(v)beta(3) expression on tumor-associated vessels of human carcinomas. Int. J. Cancer 1997. 71: 320-324.
21. Natali, P. G., Hamby, C. V., Felding-Habermann, B., Liang, B., Nicotra, M. R., Di Filippo, F., Giannarelli, D., Temponi, M. and Ferrone, S., Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res. 1997. 57: 1554-1560.
22. Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D. and Li, K. C., Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat. Med. 1998. 4: 623-626.
23. Wiedle, G., Johnson-Leger, C. and Imhof, B. A., A chimeric cell adhesion molecule mediates homing of lymphocytes to vascularized tumors. Cancer Res. 1999. 59: 5255-5263.
24. McHugh, R. S., Nagarajan, S., Wang, Y. C., Sell, K. W. and Selvaraj, P., Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. Cancer Res. 1999. 59: 2433-2437.
25. McHugh, R. S., Ahmed, S. N., Wang, Y. C., Sell, K. W. and Selvaraj, P., Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc. Natl. Acad. Sci. USA 1995. 92: 8059-8063.
26. Huang, J. H., Getty, R. R., Chisari, F. V., Fowler, P., Greenspan, N. S. and Tykocinski, M. L., Protein transfer of preformed MHC-peptide complexes sensitizes target cells to T cell cytolysis. Immunity 1994. 1: 607-613.
27. Zhang, F., Schmidt, W. G., Hou, Y., Williams, A. F. and Jacobson, K., Spontaneous incorporation of the glycosylphosphatidylinositol-linked protein Thy-1 into cell membranes. Proc. Natl. Acad. Sci. USA 1992. 89: 5231-5235.
28. van den Berg, C. W., Cinek, T., Hallett, M. B., Horejsi, V. and Morgan, B. P., Exogenous glycosyl phosphatidylinositol-anchored CD59 associates with kinases in membrane clusters on U937 cells and becomes Ca2+-signaling competent. J. Cell Biol. 1995. 131: 669-677.
29. Premkumar, D. R., Fukuoka, Y., Seviever, D., Brunschwig, E., Rosenberry, T. L., Tykocinski, M. L. and Medof, M. E., Properties of exogenously added GPI-anchored proteins following their incorporation into cells. J. Cell. Biochem. 2001. 82: 234-245.
30. Medof, M. E., Nagarajan, S. and Tykocinski, M. L., Cell-surface engineering with GPI-anchored proteins. FASEB J. 1996. 10: 574-586.
31. Adler, M., Lazarus, R. A., Dennis, M. S. and Wagner, G., Solution structure of kistrin, a potent platelet aggregation inhibitor and GP IIb-IIIa antagonist. Science 1991. 253: 445-448.
32. Juliano, D., Wang, Y., Marcinkiewicz, C., Rosenthal, L. A., Stewart, G. J. and Niewiarowski, S., Disintegrin interaction with alpha V beta 3 integrin on human umbilical vein endothelial cells: expression of ligand-induced binding site on beta 3 subunit. Exp. Cell Res. 1996. 225: 132-142.
33. Legler, D. F., Wiedle, G., Ross, F. P. and Imhof, B. A., Superactivation of integrin alphavbeta3 by low antagonist concentrations. J. Cell Sci. 2001. 114: 1545-1553.
34. Nagarajan, S., Anderson, M., Ahmed, S. N., Sell, K. W. and Selvaraj, P., Purification and optimization of functional reconstitution on the surface of leukemic cell lines of GPI-anchored Fc gamma receptor III. J. Immunol. Methods 1995. 184: 241-251.
35. Brodsky, R. A., Jane, S. M., Vanin, E. F., Mitsuya, H., Peters, T. R., Shimada, T., Medof, M. E. and Nienhuis, A. W., Purified GPI-anchored CD4DAF as a receptor for HIV-mediated gene transfer. Hum. Gene Ther. 1994. 5: 1231-1239.
36. Brunschwig, E. B., Fayen, J. D., Medof, M. E. and Tykocinski, M. L., Protein transfer of glycosyl-phosphatidylinositol (GPI)-modified murine B7-1 and B7-2 costimulators. J. Immunother. 1999. 22: 390-400.
37. Low, M. G. and Kincade, P. W., Phosphatidylinositol is the membrane-anchoring domain of the Thy-1 glycoprotein. Nature 1985. 318: 62-64.
38. Butcher, E. C. and Picker, L. J., Lymphocyte homing and homeostasis. Science 1996. 272: 60-66.
39. Imhof, B. A. and Dunon, D., Leukocyte migration and adhesion. Adv. Immunol. 1995. 58: 345-416.
40. Springer, T. A., Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994. 76: 301-314.
41. Wiedle, G., Dunon, D. and Imhof, B. A., Current concepts in lymphocyte homing and recirculation. Crit. Rev. Clin. Lab. Sci. 2001. 38: 1-31.
42. Rifkin, M. R. and Landsberger, F. R., Trypanosome variant surface glycoprotein transfer to target membranes: a model for the pathogenesis of trypanosomiasis. Proc. Natl. Acad. Sci. USA 1990. 87: 801-805.
43. Kooyman, D. L., Byrne, G. W., McClellan, S., Nielsen, D., Tone, M., Waldmann, H., Coffman, T. M., McCurry, K. R., Platt, J. L. and Logan, J. S., In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 1995. 269: 89-92.
44. Brunschwig, E. B., Levine, E., Trefzer, U. and Tykocinski, M. L., Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. J. Immunol. 1995. 155: 5498-5505.
45. Wang, L. X., Chen, B. G. and Plautz, G. E., Adoptive immunotherapy of advanced tumors with CD62 L-selectinlow tumor-sensitized T lymphocytes following ex vivo hyperexpansion. J. Immunol. 2002. 169: 3314-3320.
46. Becker, C., Pohla, H., Frankenberger, B., Schuler, T., Assenmacher, M., Schendel, D. J. and Blankenstein, T., Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat. Med. 2001. 7: 1159-1162.
47. Sambrook, J. F., Fritsch, E. F. and Maniatis, T. (Eds.), Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989.